Correlation of Galectin Family Expression with Glioblastoma Progression and Survival
International Journal of Molecular Sciences · 31.12.2025 · 27 (1) · 417
DOI: 10.3390/ijms27010417 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 31.12.2025. Verfasst von Peter Curpen und 7 weiteren Autor:innen. Beteiligte Einrichtung: Princess Alexandra Hospital, Brisbane, QLD 4102, Australia. Hauptthemen laut MEDLINE: Glioblastoma, Galectins, Gene Expression Regulation, Neoplastic, Brain Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Glioblastoma is the most aggressive primary brain malignancy, characterised by extensive intra-tumoural heterogeneity, therapy resistance, and a profoundly immunosuppressive tumour microenvironment. The galectin family, a group of β-galactoside-binding lectins, has emerged as a key regulator of tumour biology, influencing oncogenesis, immune modulation, and therapy resistance. In this study, we performed an integrative bioinformatics analysis to systematically evaluate the expression patterns, prognostic significance, genetic alterations, and functional roles of galectin family members in glioblastoma. We utilised publicly available genomic datasets and computational tools to perform our analysis, including UALCAN, GEPIA, cBioPortal, STRING, GeneMANIA, DAVID, and TIMER. We identified LGALS1, LGALS3, and LGALS9 as significantly upregulated in glioblastoma, with their overexpression correlating with adverse patient survival. Functional enrichment analysis highlighted galectin-mediated pathways involved in extracellular matrix remodelling, immune dysregulation, tumour-promoting pathways, and protein processing, suggesting their pivotal role in glioblastoma pathogenesis. We also show that transcriptional and immunological signatures suggest that galectins may regulate glioblastoma immunosuppression, extracellular matrix remodelling, and protein homeostasis. Our findings provide novel insights into the oncogenic and immunoregulatory roles of galectins in glioblastoma, establishing their potential as prognostic biomarkers and therapeutic targets.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Princess Alexandra Hospital, Brisbane, QLD 4102, Australia.
- Fiona Elsey Cancer Research Institute, Ballarat, VIC 3350, Australia.
- Federation University, Ballarat, VIC 3350, Australia.
- Department of Surgery, The University of Melbourne, The Royal Melbourne Hospital, Parkville, VIC 3050, Australia.
- Department of Integrated Oncology, Center for Integrated Oncology (CIO) Bonn, University Hospital Bonn, 53127 Bonn, Germany.
- Department of Neurosurgery, University Hospital Bonn, 53127 Bonn, Germany.
ORCID-Profile: Peter Curpen, George Kannourakis, Amit Sharma, Adrian A Achuthan, Rodney B Luwor
Zitieren
APA
Curpen, P., Ahmady, F., Carnie, B. M. H., Anderson, G. E. C., Kannourakis, G., Sharma, A., Achuthan, A. A., & Luwor, R. B. (2025). Correlation of Galectin Family Expression with Glioblastoma Progression and Survival. International Journal of Molecular Sciences, 27(1), 417. https://doi.org/10.3390/ijms27010417
Vancouver
Curpen P, Ahmady F, Carnie BMH, Anderson GEC, Kannourakis G, Sharma A, et al. Correlation of Galectin Family Expression with Glioblastoma Progression and Survival. International Journal of Molecular Sciences. 2025;27(1):417. doi:10.3390/ijms27010417
BibTeX
@article{Curpen2025,
author = {Curpen, Peter and Ahmady, Farah and Carnie, Blaine M H and Anderson, Grace E C and Kannourakis, George and Sharma, Amit and Achuthan, Adrian A and Luwor, Rodney B},
title = {Correlation of Galectin Family Expression with Glioblastoma Progression and Survival},
journal = {International Journal of Molecular Sciences},
year = {2025},
volume = {27},
number = {1},
pages = {417},
doi = {10.3390/ijms27010417}
}
EUVIMED